Agenus Inc. filings document the regulatory record for a clinical-stage immuno-oncology company developing antibody-based cancer therapies, led by the BOT+BAL program of botensilimab and balstilimab. Its Form 8-K reports cover periodic financial results, clinical-program and access-program updates, material agreements, securities-related amendments and the completed disposition of manufacturing assets with related license arrangements.
Proxy and governance filings describe board matters, executive compensation, shareholder voting items and equity awards. Other event reports document officer appointments, capital-structure changes, unregistered securities activity and legal or regulatory matters affecting the company's public-company disclosures.
ARMEN GARO H reported acquisition or exercise transactions in this Form 4 filing.
Agenus Inc. director and officer Dr. Garo H. Armen received company stock as salary instead of cash for the pay period ending June 26, 2026. He was granted 5,364 shares of common stock, representing the net amount of his salary, at a reference price of $3.03 per share, which was the closing price on June 26, 2026. These shares were issued under the Amended and Restated Agenus Inc. 2019 Equity Incentive plan and were fully vested on the date of issuance, bringing his directly held common stock to 366,256 shares. The filing also notes indirect holdings through IRA accounts and through entities such as the Garo Armen 2020 2 Year AG GRAT with 23,950 shares and the Pixie Partners general partnership with 5,000 shares, where he has only a partial pecuniary interest in the partnership’s shares.
Agenus Inc. reported results of its Annual Meeting of Stockholders held on June 16, 2026, where 27,098,077 shares, or 65.24% of shares eligible to vote, were represented, establishing a quorum. Stockholders elected Class II directors Garo Armen and Jennifer Buell for three-year terms and approved amendments to the 2019 Employee Stock Purchase Plan, increasing shares authorized from 150,000 to 200,000, and to the 2019 Equity Incentive Plan, adding 5,000,000 shares available for issuance. They also approved a one-time stock option exchange program, endorsed 2025 executive compensation in a non-binding advisory vote, and ratified KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
ARMEN GARO H reported acquisition or exercise transactions in this Form 4 filing.
Agenus Inc. executive and director Dr. Garo H. Armen received 4,925 shares of Common Stock as stock-based salary for the pay period ending June 12, 2026. The shares were valued using the closing price of $3.30 on that date and are fully vested upon issuance under the Amended and Restated Agenus Inc. 2019 Equity Incentive plan. After this grant, Dr. Armen holds 360,892 shares directly, along with additional indirect holdings through IRA accounts and entities referenced in the footnotes.
ARMEN GARO H reported acquisition or exercise transactions in this Form 4 filing.
AGENUS INC director and officer Garo H. Armen received 4,644 shares of Common Stock as compensation paid in stock instead of cash. The shares were valued at $3.50 per share, equal to the closing price on May 29, 2026, and were fully vested on the grant date.
After this grant, Dr. Armen directly holds 355,967 shares of Common Stock. He also has indirect holdings through IRA accounts and entities, including a GRAT holding 23,950 shares and a general partnership holding 5,000 shares in which he has only a partial pecuniary interest.
ARMEN GARO H reported acquisition or exercise transactions in this Form 4 filing.
Agenus Inc. director and officer Dr. Garo H. Armen received a grant of 4,540 shares of common stock for the pay period ending May 15, 2026, as salary paid in stock instead of cash. The shares were issued fully vested under the company’s 2019 equity incentive plan at a reference price of $3.58, the closing price on May 15, 2026.
Following this grant, Dr. Armen directly holds 351,323 common shares, with additional indirect holdings in IRA accounts and entities such as the Garo Armen 2020 2 Year AG GRAT and Pixie Partners, where he has only a partial pecuniary interest.
Agenus Inc. reported that its Senior Director, Financial Reporting and Compliance and Principal Accounting Officer, Austin Charette, has decided to resign. He informed the company on May 12, 2026, and his resignation will be effective May 29, 2026. The filing does not describe any replacement or changes to broader strategy, focusing solely on this leadership transition in the finance function.
Agenus Inc. reported a sharp swing to profitability for the quarter ended March 31, 2026, driven by a major manufacturing asset sale and higher royalty revenue, while still facing significant financial risk.
Total revenue rose to $33.7 million, including $29.1 million of non-cash royalty revenue from GlaxoSmithKline vaccines using its QS‑21 adjuvant and $4.6 million of pre-commercial sales of botensilimab/balstilimab through early access programs. A $40.4 million gain on the sale of its Emeryville and Berkeley manufacturing facilities to Zydus contributed to net income of $39.2 million, or $1.03 per basic share.
The Zydus collaboration brought $91.0 million in cash at closing and up to $50.0 million of additional non-cash consideration tied to future manufacturing services, while Agenus retained significant royalty and milestone obligations, including a $263.4 million liability related to prior royalty financings. Cash and cash equivalents increased to $35.0 million from $3.0 million at year-end 2025, and subsequent at-the-market share sales added $11.7 million. Despite this liquidity improvement, the company disclosed substantial doubt about its ability to continue as a going concern without additional capital, citing a $2.1 billion accumulated deficit and the need to fund late-stage development and potential commercialization of botensilimab plus balstilimab.
Agenus Inc. reported much stronger results for the quarter ended March 31, 2026, helped by its strategic collaboration with Zydus and growing early access use of its BOT+BAL immunotherapy combination. Total revenue rose to $33.7 million, up from $24.1 million a year earlier, and net income improved to a profit of $39.2 million versus a $26.4 million loss in the prior-year quarter.
Cash and cash equivalents were $35.0 million as of March 31, 2026, compared with $18.5 million a year earlier, with an additional $11.7 million raised after quarter-end through an at-the-market equity program. The Zydus collaboration, which closed in January 2026, delivered $91 million of upfront capital including $75 million in cash for U.S. manufacturing facilities and a $16 million equity investment, plus up to $50 million in contingent payments tied to BOT+BAL production orders.
Agenus highlighted that approximately 1,300 patients have been treated with botensilimab and/or balstilimab and that its global Phase 3 BATTMAN trial in refractory MSS colorectal cancer began enrolling patients in April 2026. The company is focusing operating priorities on BOT+BAL while targeting about $50 million in annualized operating expenses to support development. It also noted that the SEC concluded its investigation in May 2026 with no enforcement action recommended and that a related putative securities class action was dismissed in its entirety by a U.S. District Court in March 2026.
ARMEN GARO H reported acquisition or exercise transactions in this Form 4 filing.
Agenus Inc. director and officer Dr. Garo H. Armen received 4,233 shares of Common Stock as salary paid in stock for the pay period ending May 1, 2026. The shares were valued at $3.84, the closing price of Agenus stock on May 1, 2026, and are fully vested on issuance.
Following this grant, Dr. Armen directly holds 346,783 Agenus shares. He also has indirect holdings through IRA accounts, the Garo Armen 2020 2 Year AG GRAT with 23,950 shares, and Pixie Partners with 5,000 shares, where he has a pecuniary interest in only part of the Pixie position.